Investment in API manufacturing at Novo Nordisk

22 November 2022

Novo Nordisk (NOV: N) has announced plans to spend 5.4 billion Danish kroner ($750 million) on the expansion of existing facilities and the addition of a new plant in Bagsværd, Denmark.

This investment, which will create around 160 new jobs, will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API), to supply the company’s global clinical trials. It will provide capacity for developing the Danish firm’s future oral and injectable product portfolio.

Work on the site outside Copenhagen, where Novo Nordisk's headquarters are also located, is due to be complete in 2024. Meanwhile, the firm is moving forward with its building of an API purification factory, API recovery unit and finished products assembly pack in Kalundborg, in the west of Denmark's island of Zealand.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK